See the DrugPatentWatch profile for Xeljanz
What is Xeljanz XR?
Xeljanz XR is an extended-release formulation of tofacitinib, a Janus kinase (JAK) inhibitor. It is prescribed to treat adults with moderate to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. Tofacitinib works by blocking certain enzymes in the body that are involved in inflammation [1].
When did Xeljanz XR's patents start expiring?
The patent landscape for Xeljanz XR is complex, with various patents covering the drug, its formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiration timelines [2]. For specific patent expiration dates for Xeljanz XR, one would typically need to consult a specialized database or report that details the patent lifecycle of the drug.
What are the generic alternatives to Xeljanz XR?
As of late 2023 and early 2024, generic versions of Xeljanz XR are not yet widely available. The timeline for generic entry is dependent on patent expirations and any potential market exclusivities or legal challenges. Once primary patents expire and any associated exclusivities lapse, generic manufacturers can seek approval to market their versions of tofacitinib extended-release [2].
How does Xeljanz XR compare to the immediate-release version?
Xeljanz XR is designed for once-daily dosing, offering convenience for patients compared to the twice-daily dosing of the immediate-release (IR) formulation of tofacitinib. Both formulations contain the same active ingredient, tofacitinib, and work through the same mechanism of action by inhibiting JAK enzymes to reduce inflammation [1]. The extended-release formulation is engineered to release the drug over a longer period, maintaining therapeutic levels with less frequent administration.
What are the risks and side effects associated with Xeljanz XR?
Xeljanz XR, like other JAK inhibitors, carries a boxed warning about the risk of serious infections, including tuberculosis, invasive fungal infections, and bacterial, viral, or other infections that may be serious. It also carries warnings about malignancy, thrombosis (blood clots), and increased mortality in certain patients [1]. Common side effects can include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis [1].
Who manufactures Xeljanz XR?
Xeljanz XR is manufactured by Pfizer [1].
What is the cost of Xeljanz XR?
The cost of Xeljanz XR can vary significantly based on insurance coverage, pharmacy, and geographic location. As a branded prescription medication, it is generally considered expensive. Once generic versions become available, their prices are typically lower than the brand-name drug [2].
Are there other JAK inhibitors for these conditions?
Yes, there are other JAK inhibitors approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. These include drugs like baricitinib (Olumiant) and upadacitinib (Rinvoq), which also target JAK pathways but may have different efficacy and safety profiles [3].
---
Sources:
[1] https://www.xeljanz.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845293/